Bruker (NASDAQ:BRKR) Sees Unusually-High Trading Volume – Time to Buy?

Posted by George Bondi on May 15th, 2026

Bruker Corporation (NASDAQ:BRKR – Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 3,870,890 shares changed hands during trading, an increase of 67% from the previous session’s volume of 2,324,268 shares.The stock last traded at $44.7430 and had previously closed at $44.73.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Jefferies Financial Group set a $50.00 price objective on Bruker in a report on Thursday, February 12th. The Goldman Sachs Group cut their price target on Bruker from $40.00 to $35.00 and set a “sell” rating for the company in a research note on Friday, February 13th. Guggenheim cut their price target on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, March 30th. TD Cowen boosted their price target on Bruker from $43.00 to $45.00 and gave the company a “hold” rating in a research note on Thursday, May 7th. Finally, Weiss Ratings downgraded shares of Bruker from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Bruker has a consensus rating of “Hold” and an average price target of $50.54.

Read Our Latest Stock Report on Bruker

Bruker Stock Up 0.7%

The stock’s 50-day simple moving average is $37.66 and its 200 day simple moving average is $42.24. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The firm has a market cap of $6.72 billion, a P/E ratio of -184.00, a PEG ratio of 2.63 and a beta of 1.12.

Bruker (NASDAQ:BRKR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business had revenue of $823.40 million for the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter last year, the firm earned $0.47 EPS. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Monday, March 23rd. Bruker’s dividend payout ratio is -83.33%.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 2,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total value of $79,800.00. Following the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 27.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC purchased a new position in shares of Bruker during the 4th quarter worth $26,000. Allworth Financial LP boosted its stake in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the last quarter. Spire Wealth Management boosted its stake in shares of Bruker by 85.3% during the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after acquiring an additional 665 shares during the last quarter. Finally, Summit Securities Group LLC purchased a new position in shares of Bruker during the 4th quarter worth $50,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

(Get Free Report)

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.